Clinical Trial Update: Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial to evaluate the efficacy and safety of MY008211A in subjects with immunoglobulin A nephropathy (IgAN). The study is currently not yet rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• MY008211A

Snippet

Sponsor: Wuhan Createrna Science and Technology Co., Ltd | Conditions: IgA Nephropathy (IgAN) | Phase 2 | Status: NOT_YET_RECRUITING